NHS England agrees deal for cystic fibrosis 'wonder drug' Orkambi

Up to 5,000 patients in England will benefit from the £104,000-a-year medications Orkambi and Symkevi following the deal with Boston-based manufacturer Vertex.

Source: the Mail online | Health - October 24, 2019 Category: Consumer Health News Source Type: news